CN105726841A - Drug for treating chronic bronchitis - Google Patents

Drug for treating chronic bronchitis Download PDF

Info

Publication number
CN105726841A
CN105726841A CN201610233063.0A CN201610233063A CN105726841A CN 105726841 A CN105726841 A CN 105726841A CN 201610233063 A CN201610233063 A CN 201610233063A CN 105726841 A CN105726841 A CN 105726841A
Authority
CN
China
Prior art keywords
parts
herba
chronic bronchitis
chinese
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610233063.0A
Other languages
Chinese (zh)
Inventor
吴斌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ningbo Youmeike New Material Co Ltd
Original Assignee
Ningbo Youmeike New Material Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ningbo Youmeike New Material Co Ltd filed Critical Ningbo Youmeike New Material Co Ltd
Priority to CN201610233063.0A priority Critical patent/CN105726841A/en
Publication of CN105726841A publication Critical patent/CN105726841A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/238—Saposhnikovia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
    • A61K36/268—Asarum (wild ginger)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8888—Pinellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a drug for treating chronic bronchitis.The drug is prepared from, by weight, 10 parts of purple quartz, 9 parts of Chinese holly leaves, 6 parts of a Siberian columbine meadowrue herb, 3 parts of Chinese ephedra, 8 parts of cassia twigs, 6 parts of asarum, 6 parts of pinellia ternate, 9 parts of Chinese parsnip roots, 12 parts of astragalus membranaceus, 5 parts of giant clam and 12 parts of hibiscus syriacus.In the application of the drug, the purple quartz benefits lower origin, warms the kidney and absorbs qi; the Chinese holly leaves nourishes yin and abates fever; the Siberian columbine meadowrue herb clears away heat and toxic materials and diminishes inflammation; the Chinese ephedra and the cassia twigs free lung and relieve asthma; the asarum and the pinellia ternate warm the middle warmer, eliminate rheum, expel cold and calm the adverse-rising energy; the Chinese parsnip roots and the astragalus membranaceus eliminate evil without healthy qi damage, and the astragalus membranaceus and Chinese parsnip roots secure the exterior without evil production; the giant clam calms the nerves and removes toxic materials after entering the kidney; the hibiscus syriacus has a sweet flavor, clears lung, eliminates phlegm, removes toxic materials and relieves pain.The medicinal materials are combined for usage and jointly achieve the effects of warming yang, dredging collaterals, dispelling cold, eliminating phlegm, relieving cough and relieving asthma.A clinical experiment proves that the drug can safely and effectively treat the chronic bronchitis.

Description

A kind of medicine for treating chronic bronchitis
Technical field
The present invention relates to a kind of Chinese medicine, be specifically related to a kind of medicine for treating chronic bronchitis.
Background technology
Chronic bronchitis is the chronic nonspecific inflammation of trachea-bronchial epithelial cell mucosa and surrounding tissue thereof.Clinically with cough, expectoration or with recurrent exerbation such as asthma for cardinal symptom, annual continue 3 months, continuous more than 2 years.Early symptom is slight, and more than winter attack, spring and summer is alleviated.Late period, symptom can exist throughout the year because of increased inflammation.Its Pathologic Characteristics is bronchus glandular hyperplasia and mucosa secretion increasing.The state of an illness is slow Progressive symmetric erythrokeratodermia progress, and Chang Bingfa obstructive emphysema, pulmonary hypertension often occurs severe patient, even pulmonary heart disease.
Occurring and the invasion and attack repeatedly developing normal and exopathogen of primary disease, lung, spleen, the dirty functional disorder of kidney three are closely related.Acute attack stage, mostly because of insufficiency of lung-QI, weakened defensive QI exopathogen is invaded, so that cough recurrent exerbation；Or because of chronic cough endlessly, recurrent exerbation, or body is empty with age, lung spleen deficiency of kidney-QI, water Tianjin not cloth, stops, check in lung in phlegm retention, causes long-term cough with asthma, or because ingest, the factor such as drink injure in lung, and then form primary disease.Pathological changes is prolonged not to heal, then lung spleen undermines in kidney, therefore the person of being in a bad way is often accompanied by asthma and can not put down sleeping, dynamic then more so failure of the kidney in receiving QI such as grade time.
Clinical manifestation
How slow symptom onset is, and the course of disease is longer, and some patients premorbid has the acute respiratory infection histories such as acute bronchitis, influenza or pneumonia, develops into primary disease due to protracted course of disease.Cardinal symptom is chronic cough, expectoration and breathes hard or with panting.The symptom initial stage is relatively light, and along with course advancement, because of recurrent respiratory tract infection, acute attack is more frequent, and symptom is also more serious, especially with winter for very.
1. cough: the cough of initial stage daystart is heavier, daytime is relatively light, and night in late period is also obvious, often has apasm of coughing to show effect, and accompany expectoration before sleeping.This is that secretions accumulates in caused by bronchial lumen owing to bronchial mucosa is congested, edema.Along with PD, cough is not healed all the year round.
2. expectoration: especially many with daystart expectoration, sputum is generally white mucus or serosity spumescence, occasionally can band blood.During this polyphyly nighttime sleep, coughre flex is blunt, air flue intracavity sputum pile up, daystart get up after because of position variation cause stimulation expectoration therefore.When acute attack is infected with antibacterial, amount of expectoration increases, and sputum then becomes sticky or purulence.
3. breathe hard and pant: how inconspicuous the course of disease initial stage is, when course advancement merge obstructive emphysema time then engender different the breathing hard of light and heavy degree, with after activity more so.Chronic bronchitis merges asthma or the patient of so-called chronic asthmatic bronchitis, especially when acute attack, the symptom panted often occurs, and is often accompanied by wheezing sound.
The diagnosis of this disease relies primarily on lab testing 1. x-ray inspection: early stage is often negative.Along with the progress of pathological changes, bronchial wall thickens, and bronchioles or alveolar spaces have inflammatory cell infiltration, X-ray film can find two lung marking increase, and in strip or netted, lower field is more than upper field.When being developed to emphysema, then the bright degree of lung field increases, and diaphragm declines and smooth, and activity weakens, and intercostal space is broadening.2. pulmonary function test: early stage, acute attack stage may occur in which that closing volume CV increase and maximal voluntary ventilation and 1 second expiration amount lower, and can recover to normally after treatment without substantially changing.If lung function tests during Complicated with Pulmonary edema due to disorder of QI, there is bigger help.3. Sputum culturing: may separate out the pathogenic bacterium such as hemophilus influenza, Diplococcus pneumoniae, alpha streptococcus.4. acute attack stage numeration of leukocyte and neutrophil count can increase.Type of panting blood eosinophils increase.
Drug therapy is anti-infectives 1.: the result of antibiotic sensitivity test carries out the selection of anti-infectives according to Sputum bacterial culture, to not can determine that pathogen person can take experiential therapy, and conventional penicillin, Sulfamethoxazole/trimethoprim etc..2. bronchodilator: dust head has anticholinergic agents, such as ipratropium bromide (ipratropium bromide)；Beta receptor excitomotor, such as albuterol；Theophylline class medicine, such as aminophylline.3. expectorant, dust head has ambroxol, carbocisteine.4. Treating Chronic Bronchitis with Traditional Chinese Medicine can use traditional Chinese medical herbal treatment, and effectiveness comparison is desirable.Simultaneously it should be noted that diet and living habit.
Medical material involved in the present invention is all recorded in " China's book on Chinese herbal medicine " as seen.
Summary of the invention
It is desirable to provide a kind of medicine for treating chronic bronchitis, by selecting suitable medical material and proportioning thereof, reach safely and effectively to cure the purpose of chronic bronchitis.
In order to achieve the above object, the present invention is by the following technical solutions:
A kind of medicine for treating chronic bronchitis, it is characterized in that, it is to be prepared from by the raw medicinal material of following weight proportion: Fluoritum 10 parts, Folium Mahoniae 9 parts, Herba thalictri sibirici 6 parts, 3 parts of Herba Ephedrae, Ramulus Cinnamomi 8 parts, Herba Asari 6 parts, the Rhizoma Pinelliae 6 parts, Radix Saposhnikoviae 9 parts, the Radix Astragali 12 parts, Concha Tridacna squamosa 5 parts, towards emperor 12 parts.
Illustrate the method have the benefit that below in conjunction with theories of Chinese materia medica
It has been recognised by the inventors that the basic pathogenesis of chronic bronchitis is mainly reflected as lung, spleen, kidney three deficiency of five ZANG-organs damage, and their mutual relation is unbalance, simultaneously the more sophisticated because of the participation of the factors such as expectorant, fire, the stasis of blood again.Under normal circumstances, lung governing qi, department breathes, and main Xuan Fasu drops, outer conjunction fur, the passage of the lifting that comes in and goes out for mechanism of qi.The spleen has the function to transport and transform nutrients, occupies middle Jiao, for the pivot of rising and falling of QI.Insufficiency of the spleen can not transmitting and distributing the fluids, poly-wet as expectorant, on damp-phlegm, stain is in lung, affects the unobstructed of mechanism of qi and sees cough with asthma, the disease such as cough up phlegm.Kidney governing inspiration, kidney yang virtual loss, gas loses and takes the photograph and receive, decline of the fire from the gate of life, body fluid defeatedization mistake department, and lung qi lifting is obstructed, and gasification function is not normal, aqueous vapor can not Xuanhua, for expectorant for drinking, obstructing airway；Damage of kidney-YIN, vehement in asthenic fire, lung Tianjin of burning, all can make impairment of dispersing and descending function of the lung, abnormal rising of lung-QI and cough with asthma is coughed up phlegm.Treatment should warming YANG dredging collateral, cold expelling eliminates the phlegm, and takes the photograph and receives and the respectful important department dropped regulating lung kidney.
The present invention uses: unit, the kidney warming improving inspiration by invigorating kidney-QI under Fluoritum tonification；Folium Mahoniae nourishing YIN for decreasing fever；The heat-clearing and toxic substances removing antiinflammatory cold in nature of Herba thalictri sibirici bitter in the mouth；Herba Ephedrae, Ramulus Cinnamomi, depressed lung-energy dispersing；Herba Asari, Rhizoma Pinelliae warming middle-JIAO exempt from drink, expelling cold pathogen and lowering adverse QI；Radix Saposhnikoviae joins the Radix Astragali, eliminating evil and just do not hinder, and the Radix Astragali obtains Radix Saposhnikoviae, consolidating superficial resistance and do not stay heresy；Concha Tridacna squamosa enters kidney and calms the nerves removing toxic substances；Towards the flat removing heat from the lung and dissipating phlegm of emperor's sweet in the mouth, the removing toxic substances all medicines of pain relieving share, and play warming YANG dredging collateral altogether, and cold expelling eliminates the phlegm, cough-relieving, the merit relievingd asthma.
Below in conjunction with clinical laboratory data, beneficial effects of the present invention is described:
1, physical data
Inventor collects 228 example thrombophlebitis patients between 2011 03 month-2014 years 03 month altogether.It is randomly divided into: treatment group 132 example, matched group 96 example.In treatment group 132 example patient, male 70 examples, female 62 example；38 ~ 79 years old age, 60.12 years old mean age；In matched group 96 example patient, male 52 examples, female 44 example；40 ~ 78 years old age, 58.36 years old mean age.The data such as two groups of sexes, age, courses of disease there was no significant difference, and has comparability.
Diagnostic criteria
1. clinically to cough, to spit for cardinal symptom or with panting, annual morbidity continues 3 months, and continuous 2 years or above (though cough clinically, expectorant, asthma shape continuous 2 years or more than, but annual morbidity continues the patient less than 3 months, if any clear and definite objective determination according to such as x-ray, pulmonary function etc. is also diagnosable.But still lack the diagnostic criteria of these objective determinations at present, need to be studied and defined further from now on).
2. the Other diseases (such as pulmonary tuberculosis, pneumoconiosis, pulmonary abscess, heart disease, cardiac insufficiency, bronchiectasis, bronchial asthma, chronic nasopharynx illness etc.) with cough, wheezing symptoms is got rid of.
The inclusive criteria 1. age was more than 18 years old；2. the diagnostic criteria of chronic bronchitis is met；3. clinical manifestation is that dyspnea, cough, amount of expectoration increase and purulent sputum, peripheral white blood cell more than 10*109/L or neutrophilic granulocyte number more than 75%；4. without severe cardiac, liver, kidney and disease of hematopoietic system, and need not oral or intravenous glucocorticoid person during treating.
Exclusion standard is 1. to trial drug allergy sufferers；2. immunodeficiency person；3. state of an illness weight, and need hospitalization patient.
2, Therapeutic Method
The capsule that the oral present invention specific embodiment 3 for the treatment of group prepares, every day 3 times.Treat 14.
Matched group is administered orally Sulfamethoxazole, 2 pieces/times, 2 times/d；Aminophylline, 0.1g/ time, 3 times/d.Treat 14.
3, criterion of therapeutical effect and therapeutic outcome
3.1 criterions of therapeutical effect
1. recovery from illness: symptom and the not enough slight person of pulmonary wheezing sound, or cough, expectorant, asthma shape take a turn for the better more than 9 one-tenths, X-ray film display recovers normally, and etiological examination shows that Sputum culturing is turned out cloudy；
2. effective: cough, expectorant, asthma shape take a turn for the better 6 one-tenths above or symptoms and pulmonary's wheezing sound is clearly better (+++ →+), and X-ray film show the front improvement of relatively treatment, and etiological examination shows that Sputum culturing is turned out cloudy substantially or pathogenic bacterium disappear substantially；
3. effective: to cough, expectorant, breathe heavily improvement more than 3 one-tenths, or symptom and pulmonary wheezing sound take a turn for the better (+++ → ++, or ++ →+), X-ray film takes a turn for the better before show relatively treatment, and etiological examination shows that Sputum culturing shows positive；
4. invalid: symptom and pulmonary's wheezing sound are without change, or improvement is less than 3 one-tenth persons, and symptom and pulmonary's wheezing sound add severe one, X-ray film inspection and etiological examination have no significant change before relatively treating.
3.2 treatment statistical results are in Table 1.
1 liang of table group comparitive study
Group n Recovery from illness Effective Effectively Invalid Total effective rate (%) Obvious adverse reaction example
Treatment group 132 32 78 10 12 90.91% 0
Matched group 96 18 45 12 21 78.13% 0
Visible, chronic bronchitis can safely and effectively be treated by the medicine that the present invention prepares, and cure rate is high.
Detailed description of the invention
In order to be more fully understood that and implement the present invention, further illustrate the present invention below in conjunction with specific embodiment.
Embodiment 1
Weigh: Fluoritum 10 grams, Folium Mahoniae 9 grams, Herba thalictri sibirici 6 grams, 3 grams of Herba Ephedrae, Ramulus Cinnamomi 8 grams, Herba Asari 6 grams, the Rhizoma Pinelliae 6 grams, Radix Saposhnikoviae 9 grams, the Radix Astragali 12 grams, Concha Tridacna squamosa 5 grams, towards emperor 12 grams；Add 8 times amount water, decoct 1.5 hours, filter；Filtering residue adds 6 times amount water, decocts 1 hour, filters；Merging filtrate, is concentrated into 120 grams, must meet the decoct of one day consumption of adult normal.
For treating chronic bronchitis.Oral, daily once.
Embodiment 2
Weigh: Fluoritum 10 grams, Folium Mahoniae 9 grams, Herba thalictri sibirici 6 grams, 3 grams of Herba Ephedrae, Ramulus Cinnamomi 8 grams, Herba Asari 6 grams, the Rhizoma Pinelliae 6 grams, Radix Saposhnikoviae 9 grams, the Radix Astragali 12 grams, Concha Tridacna squamosa 5 grams, towards emperor 12 grams；Add 10 times amount water, decoct 2 hours, filter；Filtering residue adds 8 times amount water, decocts 1.5 hours, filters；Merging filtrate, concentration, dry, packaging, the powder of one day consumption of adult normal must be met.
For treating chronic bronchitis.Oral, every bu is taken for twice sooner or later.
Embodiment 3
Weigh: Fluoritum 10 grams, Folium Mahoniae 9 grams, Herba thalictri sibirici 6 grams, 3 grams of Herba Ephedrae, Ramulus Cinnamomi 8 grams, Herba Asari 6 grams, the Rhizoma Pinelliae 6 grams, Radix Saposhnikoviae 9 grams, the Radix Astragali 12 grams, Concha Tridacna squamosa 5 grams, towards emperor 12 grams；Add 6 times amount water, decoct 3 times, decoct 1 hour every time, merge decoction liquor, concentration, dry, load capsule shells, the capsule of one day consumption of adult normal must be met.
For treating chronic bronchitis.Oral, every bu morning, noon and afternoon take for three times.

Claims (4)

1. the medicine being used for treating chronic bronchitis, it is characterized in that, it is to be prepared from by the raw medicinal material of following weight proportion: Fluoritum 10 parts, Folium Mahoniae 9 parts, Herba thalictri sibirici 6 parts, 3 parts of Herba Ephedrae, Ramulus Cinnamomi 8 parts, Herba Asari 6 parts, the Rhizoma Pinelliae 6 parts, Radix Saposhnikoviae 9 parts, the Radix Astragali 12 parts, Concha Tridacna squamosa 5 parts, towards emperor 12 parts.
2. the medicine for treating chronic bronchitis as claimed in claim 1, it is characterized in that, its preparation method is: weigh: Fluoritum 10 parts, Folium Mahoniae 9 parts, Herba thalictri sibirici 6 parts, 3 parts of Herba Ephedrae, Ramulus Cinnamomi 8 parts, Herba Asari 6 parts, the Rhizoma Pinelliae 6 parts, Radix Saposhnikoviae 9 parts, the Radix Astragali 12 parts, Concha Tridacna squamosa 5 parts, towards emperor 12 parts；Add 8 times amount water, decoct 1.5 hours, filter；Filtering residue adds 6 times amount water, decocts 1 hour, filters；Merging filtrate, is concentrated into 120 parts, obtains decoct；Above-mentioned part each means weight portion.
3. the medicine for treating chronic bronchitis as claimed in claim 1, it is characterized in that, its preparation method is: weigh: Fluoritum 10 parts, Folium Mahoniae 9 parts, Herba thalictri sibirici 6 parts, 3 parts of Herba Ephedrae, Ramulus Cinnamomi 8 parts, Herba Asari 6 parts, the Rhizoma Pinelliae 6 parts, Radix Saposhnikoviae 9 parts, the Radix Astragali 12 parts, Concha Tridacna squamosa 5 parts, towards emperor 12 parts；Add 10 times amount water, decoct 2 hours, filter；Filtering residue adds 8 times amount water, decocts 1.5 hours, filters；Merging filtrate, concentration, dry, packaging, obtain powder；Above-mentioned part each means weight portion.
4. the medicine for treating chronic bronchitis as claimed in claim 1, it is characterized in that, its preparation method is: weigh: Fluoritum 10 parts, Folium Mahoniae 9 parts, Herba thalictri sibirici 6 parts, 3 parts of Herba Ephedrae, Ramulus Cinnamomi 8 parts, Herba Asari 6 parts, the Rhizoma Pinelliae 6 parts, Radix Saposhnikoviae 9 parts, the Radix Astragali 12 parts, Concha Tridacna squamosa 5 parts, towards emperor 12 parts；Add 6 times amount water, decoct 3 times, decoct 1 hour every time, merge decoction liquor, concentration, dry, load capsule shells, obtain capsule；Above-mentioned part each means weight portion.
CN201610233063.0A 2016-04-15 2016-04-15 Drug for treating chronic bronchitis Pending CN105726841A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610233063.0A CN105726841A (en) 2016-04-15 2016-04-15 Drug for treating chronic bronchitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610233063.0A CN105726841A (en) 2016-04-15 2016-04-15 Drug for treating chronic bronchitis

Publications (1)

Publication Number Publication Date
CN105726841A true CN105726841A (en) 2016-07-06

Family

ID=56254368

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610233063.0A Pending CN105726841A (en) 2016-04-15 2016-04-15 Drug for treating chronic bronchitis

Country Status (1)

Country Link
CN (1) CN105726841A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022119352A1 (en) * 2020-12-03 2022-06-09 (주)에스디생명공학 Antitussive and mucoactive composition comprising extract of hibiscus syriacus l. as active ingredient

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1463708A (en) * 2001-12-18 2003-12-31 魏生 Oral liquid for treating common cold and coughing
CN101940773A (en) * 2010-09-10 2011-01-12 重庆市南川区金佛山中药材品种培育研究所 Chinese medicinal herb for treating chronic bronchitis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1463708A (en) * 2001-12-18 2003-12-31 魏生 Oral liquid for treating common cold and coughing
CN101940773A (en) * 2010-09-10 2011-01-12 重庆市南川区金佛山中药材品种培育研究所 Chinese medicinal herb for treating chronic bronchitis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022119352A1 (en) * 2020-12-03 2022-06-09 (주)에스디생명공학 Antitussive and mucoactive composition comprising extract of hibiscus syriacus l. as active ingredient

Similar Documents

Publication Publication Date Title
CN1843499A (en) Traditional Chinese medicine formulation for treating bronchitis and tonsillitis
CN102940832A (en) Medicament for treating chronic bronchitis and preparation method thereof
CN100389803C (en) Chinese medicinal composition for treating wind-heat cold and preparation method thereof
CN101874880B (en) Method for preparing traditional Chinese medicine for treating pediatric wind-heat lung obstruction type pneumonia asthma
CN101757386B (en) Preparation method of traditional Chinese medicine for treating infantile capillary bronchitis
CN101474377B (en) Chinese medicine prescription for treating chronic bronchitis
CN100579557C (en) Cough-stopping granule with honeysuckle flower and bulbus fritilariae
CN101843840B (en) Chinese medicinal compound granules for treating acute exacerbation of chronic obstructive pulmonary disease
CN104225404B (en) A kind of pharmaceutical composition and its preparation for treating pulmonary fibrosis
CN100553666C (en) Medicine of treatment chronic pulmonary heart disease and preparation method thereof
CN105726841A (en) Drug for treating chronic bronchitis
CN100534526C (en) Chinese medicine for treating respiratory disease
CN108498743A (en) A kind of prescription for treating Chronic Obstructive Pulmonary Disease syndrome of deficiency of lung qi
CN103768471B (en) A kind of Chinese medicine composition of cough-relieving and its preparation method and application
CN102205037B (en) Oral medicinal composition for treating infantile bronchitis caused by bacterial infection and preparation method thereof
CN101647866A (en) Traditional Chinese medicine decoction for relieving cough and dispelling phlegm
CN109771559A (en) A kind of Chinese medicine composition and preparation method thereof for treating pulmonary interstitial fibrosis
CN105327182A (en) Medicine for treating child pertussis and preparation method thereof
CN102836203A (en) Traditional Chinese medicine composition for treating wind-heat type common cold as well as preparation method and application thereof
CN109453325A (en) A kind of Chinese medicine composition and its preparation method and application for treating respiratory disease
CN108355124A (en) A kind of Chinese medicine composition that treating Air way mucus hypersecretion and its application
CN102233026B (en) Pharmaceutical composition and preparation method and application thereof
CN115089689B (en) Traditional Chinese medicine composition for treating spasmodic cough as well as preparation method and application thereof
CN105497315A (en) Medicine for treating pulmonary interstitial fibrosis
CN110585281B (en) Children and adults common traditional Chinese medicine preparation for treating phlegm-heat obstructing lung and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160706